Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial

Nagata, Kazuma; Kikuchi, Takashi; Horie, Takeo; Shiraki, Akira; Kitajima, Takamasa; Kadowaki, Toru; Tokioka, Fumiaki; Chohnabayashi, Naohiko; Watanabe, Akira; Sato, Susumu; Tomii, Keisuke

doi:10.1513/annalsats.201706-425oc

Cited by 98 publications

(115 citation statements)

References 35 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…There are limited data over a longer time frame but two studies have examined the addition of NHF to long‐term oxygen therapy (LTOT) . Nagata et al recruited 32 people with COPD and hypercapnic respiratory failure. NHF at a mean flow of around 30 L/min lowered PaCO 2 by 4.1 mm Hg relative to the control group at 6 weeks.…”

Section: Discussionmentioning

confidence: 99%

Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial

et al. 2019

View full text Add to dashboard Cite

Background and objective: Non-invasive ventilation (NIV) is part of the standard of care for hypercapnic respiratory failure secondary to COPD, but may be poorly tolerated. Preliminary evidence suggests nasal high-flow (NHF) therapy may improve hypercapnia in COPD and be well tolerated. We compared NHF and NIV in people with COPD and chronic hypercapnic respiratory failure. Methods: Single-blind randomized controlled two-way cross-over single-centre trial was conducted in New Zealand. Twenty-four participants with stable hypercapnic COPD received: NHF at 45 L/min and NIV at 15/4 cm H 2 O, each for 60 min with a 15-min washout in between. The primary outcome was transcutaneous partial pressure of carbon dioxide (PtCO 2 ) at 60 min, adjusted for baseline. Results: NIV reduced the PtCO 2 more than NHF (mean (SD) at 60 min by −5.3 (5.0) vs −2.5 (3.5) mm Hg; difference: −2.8 (−5.0 to −0.5) P = 0.021). Difference across all time points was −2.5 mm Hg (95% CI −4.5 to −0.5, P = 0.016). There was no significant difference in the proportion of participants with a reduction of PtCO 2 ≥ 4 or ≥ 8 mm Hg. Participants rated NHF significantly better for ease of application, comfort and fit. Conclusion: In stable COPD patients with chronic hypercapnia, NIV resulted in a greater reduction in PtCO 2 compared with NHF, which was of uncertain clinical significance. NHF was better tolerated than NIV and may be a therapeutic option for some people with hypercapnic respiratory failure. Clinical Trial Registration: ACTRN12616001701415 at www.anzctr.org.au

show abstract

Section: Discussionmentioning

confidence: 99%

Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The improvement in dyspnoea scores was most apparent at 3 months of treatment. In another home‐based study on subjects with stable COPD, NHF in combination with O 2 improved quality‐of‐life measures compared to O 2 alone . These findings may add further merit to the case for exploring the role of NHF in selected home‐based circumstances of symptomatic breathlessness.…”

mentioning

confidence: 81%

Nasal high‐flow therapy: Established roles and emerging opportunities

Mansfield

2019

Respirology

View full text Add to dashboard Cite

show abstract

“…(van Velzen et al, 2017) A small pilot RCT (n = 29) reported that six weeks of high-flow nasal cannula oxygen therapy reduced hypercapnia and improved health-related quality of life in patients with stable hypercapnic COPD. (Nagata et al, 2018) Once patients improve and can tolerate at least 4 hours of unassisted breathing, NIV can be directly discontinued without any need for a "weaning" period. (…”

Section: Chaptermentioning

confidence: 99%

Lungenexperten diskutieren den Steroideinsatz bei COPD

Pampel¹

2019

Pneumo News

View full text Add to dashboard Cite

When the Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was initiated in 1998, a goal was to produce recommendations for management of COPD based on the best scientific information available. The first report, Global Strategy for Diagnosis, Management and Prevention of COPD was issued in 2001. In 2006 and again in 2011 a complete revision was prepared based on published research. These reports, and their companion documents, have been widely distributed and translated into many languages and can be found on the GOLD website (www.goldcopd.org). The GOLD Science Committee ‡ was established in 2002 to review published research on COPD management and prevention, to evaluate the impact of this research on recommendations in the GOLD documents related to management and prevention, and to post yearly updates on the GOLD website. Its members are recognized leaders in COPD research and clinical practice with the scientific credentials to contribute to the task of the Committee and are invited to serve in a voluntary capacity.

show abstract

Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial

Cited by 98 publications

References 35 publications

Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial

Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial

Nasal high‐flow therapy: Established roles and emerging opportunities

Lungenexperten diskutieren den Steroideinsatz bei COPD

Contact Info

Product

Resources

About